Odagiri K, Morikawa T, Naiki T, Sugiyama Y, et al. Eosinophil Proportion May Serve as a Candidate Biomarker for Adverse Events in Patients With Urothelial Carcinoma Treated With Enfortumab Vedotin. Cancer Med 2026;15:e72252.
PMID: 42681561